RT Journal Article SR Electronic T1 Impact of Itraconazole on the Survival of Heavily Pre-treated Patients with Triple-Negative Breast Cancer JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 3839 OP 3844 VO 34 IS 7 A1 HIROSHI TSUBAMOTO A1 TAKASHI SONODA A1 KAYO INOUE YR 2014 UL http://ar.iiarjournals.org/content/34/7/3839.abstract AB Background/Aim: Recurrent triple-negative breast cancer (TNBC) patients have poor prognoses and limited treatment options, especially after progression during prior chemotherapy. The present study aimed to determine the impact of itraconazole with chemotherapy in these patients. Patients and Methods: Medical records of recurrent TNBC patients receiving itraconazole with chemotherapy between 2008 and 2012 were retrospectively reviewed. Results: Thirteen patients who progressed during prior chemotherapy (12 with visceral organ metastases) were enrolled. All patients had received docetaxel, carboplatin, and gemcitabine with itraconazole. Additionally, 3 patients with pleural effusion and 2 with inflammatory breast cancer received bevacizumab. No febrile neutropenia, platelet transfusion, or chemotherapy-related death was observed during treatment with itraconazole. The response rate, median progression-free survival, and median overall survival were 62% (95% confidence interval (CI): 35-88%), 10.8 months (95%CI: 7.6-15.3 months), and 20.4 months (95%CI: 13.1-41.4 months), respectively. Conclusion: Chemotherapy with itraconazole is promising for heavily pre-treated TNBC patients.